Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results
Growing body of clinical evidence supports transformational potential of Vaxart’s oral vaccine platform Clinical trial programs on track for reporting key data milestones Ended third quarter... | November 8, 2022
Source: marketscreener.com